Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bladder cancer
Pharma
FDA signs off on UroGen's Zusduri after advisory committee snub
Zusduri is the first approved therapy for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
Zoey Becker
Jun 13, 2025 8:56am
Pfizer partner touts HER2 ADC trial win in bladder cancer
May 12, 2025 10:59am
AZ's Imfinzi checks off a win in high-risk bladder cancer study
May 9, 2025 10:14am
J&J puts ImmunityBio on defense mode in bladder cancer
Apr 27, 2025 12:35pm
AZ's Imfinzi wins perioperative FDA nod in bladder cancer
Mar 31, 2025 12:34pm
ImmunityBio, SII win FDA nod to help combat BCG shortage
Feb 19, 2025 9:01am
